BFRI earnings analysis
What we found in BFRI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Q2 2026 operating results improved substantially versus both Q1 2026 and Q2 2025: revenue increased to $12.003 million and diluted EPS improved to a $(0.05) loss. The supplied filing text does not disclose gross margin, operating margin, free cash flow, segment results, balance-sheet data, or quantitative guidance, so the broader earnings-quality and liquidity assessment is incomplete. Controls were deemed effective as of June 30, 2026, but the company provided no updated Item 1A risk-factor disclosure.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue rebounded strongly
- Q2 2026 revenue was $12.003 million, up approximately 20% from $10 million in Q1 2026 and 33% from $9 million in Q2 2025. Revenue also exceeded the supplied $9.4 million estimate by approximately 27.7%.
- EPS loss narrowed materially
- Reported Q2 2026 diluted EPS was $(0.05), improving from $(0.41) in Q1 2026 and $(0.57) in Q2 2025; it was better than the supplied $(0.07) estimate.
- Disclosure controls remain effective
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026, according to Item 4.
- No material control changes
- The filing reports that there were no changes in internal control over financial reporting during the quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, controls.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- No updated risk-factor disclosure
- The 10-Q does not provide an updated risk-factor discussion: Item 1A states that, as a smaller reporting company, Biofrontera is not required to provide this disclosure. This limits visibility into changes in operating, financing, and market risks since the last full risk assessment.
- Amended incentive plan may dilute equity
- Exhibit 10.1 is an amended and restated 2021 Omnibus Incentive Plan. The filing does not provide a share authorization, dilution amount, or compensation expense impact, leaving potential equity-dilution exposure unquantified.
- Legal-contingency exposure unclear
- Legal proceedings are referenced in Note 17 under Item 1 of Part II, but the supplied filing excerpt provides no monetary exposure or case-level detail. Potential contingency exposure therefore cannot be quantified from the available text.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.05
What they said about what is next.
No quantitative revenue or EPS outlook is provided in the supplied 10-Q text. The filing states in Item 1A that, as a smaller reporting company, Biofrontera is not required to provide risk-factor disclosure; no MD&A outlook or liquidity outlook text was supplied.
The filing reads better than the one before it.
What came before.
- 10-K · July 22, 2026
- This is a procedural Form 10-K/A rather than a new operating or financial disclosure: it adds an amended-and-restated bylaws exhibit and makes minor exhibit-index changes only. It contains no financial statements,…
- 10-Q · May 14, 2026
- Biofrontera reported Q1 2026 results with revenue of $10.1 million, surpassing previous projections, while EPS of -$0.41 fell short of estimates of -$0.08. The company experienced a 17.4% increase in product revenues…
- 10-K · March 19, 2026
- Biofrontera completed a material Strategic Transaction on October 20, 2025 to acquire U.S. rights to Ameluz and the RhodoLED lamps, positioning the company to commercialize PDT more directly in the U.S. The company…
- 10-Q · November 12, 2025
- Biofrontera reported Q3 product revenue of $6,988 (thousands) and GAAP loss per share of $(0.62). Gross margin remained high at ~70.7% but operating loss widened to $(6,278) and the company continues to burn cash,…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BFRI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever